Last mentioned: Mar 18, 2026
ClearPoint Neuro (CLPT) achieved record full-year 2025 revenue of $37 million, driven by a 23% fourth-quarter surge in its Biologics and Drug Delivery segment. The company is pivoting toward a higher-growth profile through the integration of Eris Holdings and IRRAS, setting an ambitious revenue target of up to $56 million for 2026.
This page surfaces every story mentioning Eris Holdings Inc. across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Eris Holdings Inc. was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |